80,893 Shares in HealthEquity, Inc. $HQY Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company acquired a new position in shares of HealthEquity, Inc. (NASDAQ:HQY) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 80,893 shares of the company’s stock, valued at approximately $7,306,000. The Manufacturers Life Insurance Company owned approximately 0.10% of HealthEquity as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of HealthEquity in the second quarter worth $1,018,621,000. William Blair Investment Management LLC acquired a new position in HealthEquity during the fourth quarter valued at $169,956,000. Wasatch Advisors LP lifted its stake in HealthEquity by 10.5% in the 2nd quarter. Wasatch Advisors LP now owns 7,960,735 shares of the company’s stock worth $719,014,000 after acquiring an additional 757,801 shares in the last quarter. Norges Bank purchased a new stake in HealthEquity in the 4th quarter worth about $66,927,000. Finally, Bank of New York Mellon Corp acquired a new stake in HealthEquity during the 2nd quarter worth about $60,177,000. 99.55% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other HealthEquity news, EVP Michael Henry Fiore sold 2,354 shares of the business’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $95.00, for a total value of $223,630.00. Following the completion of the sale, the executive vice president owned 52,244 shares of the company’s stock, valued at $4,963,180. The trade was a 4.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian T. Dillon sold 7,632 shares of the company’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total value of $798,383.52. Following the sale, the director owned 62,395 shares of the company’s stock, valued at approximately $6,527,140.95. This trade represents a 10.90% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 12,456 shares of company stock valued at $1,256,664 over the last quarter. 1.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Wall Street Zen upgraded HealthEquity from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. BTIG Research restated a “buy” rating and set a $115.00 price target on shares of HealthEquity in a report on Friday. Weiss Ratings raised shares of HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, June 5th. Royal Bank Of Canada upped their price objective on shares of HealthEquity from $100.00 to $108.00 and gave the company an “outperform” rating in a research note on Wednesday, June 3rd. Finally, Citigroup reiterated a “market outperform” rating on shares of HealthEquity in a research report on Friday. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.93.

HealthEquity Price Performance

Shares of HQY opened at $96.37 on Monday. The firm has a market cap of $7.97 billion, a PE ratio of 34.79, a PEG ratio of 1.53 and a beta of 0.21. The firm’s 50 day moving average price is $98.16 and its 200 day moving average price is $87.93. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.99 and a current ratio of 2.99. HealthEquity, Inc. has a twelve month low of $72.76 and a twelve month high of $107.62.

HealthEquity (NASDAQ:HQY) last posted its earnings results on Thursday, August 27th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.19 by $0.05. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The company had revenue of $350.73 million during the quarter, compared to the consensus estimate of $349.22 million. The firm’s quarterly revenue was up 95.5% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. As a group, research analysts expect that HealthEquity, Inc. will post 3.92 EPS for the current fiscal year.

More HealthEquity News

Here are the key news stories impacting HealthEquity this week:

• Positive Sentiment: HealthEquity exceeded expectations with adjusted earnings of $1.24 per share versus the $1.19 consensus, while revenue reached $350.7 million, slightly above estimates. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Profitability improved, with net income rising 10% to $65.6 million and net margin expanding to 19% from 18%. Adjusted EBITDA grew 11% to $167 million, while its margin increased to 48% from 46%. HealthEquity Second-Quarter Financial Results
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. Record HSA assets of $37.9 billion provide additional support for the company’s long-term growth outlook. HealthEquity Raises Fiscal 2027 Guidance
• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and raised its price target to $115. Another analysis indicated that HQY could be approximately 19% undervalued after the guidance increase, reinforcing the bullish interpretation of the earnings update. BTIG Research Rating HealthEquity Could Be Undervalued
• Neutral Sentiment: Fiscal 2027 revenue guidance of approximately $1.4 billion was broadly in line with expectations, so the guidance improvement was driven mainly by stronger anticipated earnings and margins.
• Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares valued at approximately $798,000, reducing his position by 10.9%. The sale was executed under a pre-arranged Rule 10b5-1 plan, which reduces its negative signaling value but could still attract investor attention. HealthEquity Director Stock Sale
• Negative Sentiment: HQY trades at a premium valuation of roughly 35 times earnings. After the recent advance toward its 52-week high, some investors may lock in gains, potentially tempering the stock’s reaction to otherwise favorable fundamentals.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.